Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sorted Muscle Progenitor Cells Reverse Muscular Dystrophy in a Mouse Model

By Biotechdaily staff writers
Posted on 07 Feb 2008
A recent report described the isolation of specific muscle tissue progenitor cells from a general population of embryonic stem cells and their potential use as a treatment for muscular dystrophy.

Investigators from the University of Texas Southwestern Medical Center (Dallas, USA) worked with a mouse model of human Duchenne muscular dystrophy that lacked the gene for the protein dystrophin.

Dystrophin is a rod-shaped cytoplasmic protein, and a vital part of a protein complex that connects the cytoskeleton of a muscle fiber to the surrounding extracellular matrix through the cell membrane. More...
Dystrophin has the longest gene known to date, measuring 2.5 megabases (0.1% of the human genome). Its gene's locus is Xp21 and has 97 exons, produces an mRNA of 14.6 kilobases and a protein of over 3500 amino acid residues.
To stimulate dystrophin production in embryonic stem cells, the investigators activated the Pax3 gene, which functions in muscle progenitor cells. However, when these cells were injected into mouse muscle, they caused the formation of teratomas, tumors containing cells of many different types of tissue.

To avoid tumor formation, the investigators utilized a fluorescent cell sorting process to concentrate muscle progenitor cells while rejecting undifferentiated, tumorogenic cells. Results published in the January 20, 2008, online edition of the journal Nature Medicine revealed that after the sorted cells were injected into the mice, they deeply penetrated the muscle tissue forming new muscle fiber. Many of the new muscle fiber cells contained dystrophin. Furthermore, after three months, the mice showed no signs of tumors.

"The problem had been that embryonic stem cells make everything,” explained senior author Dr. Rita Perlingeiro, assistant professor of developmental and molecular biology at the University of Texas Southwestern Medical Center. "They make a great variety of cells. The trick is to pull out only the one type you want. Even if there are 10 undesirable cells, that is too many. We envision eventually developing a stem-cell therapy for humans with muscular dystrophy, if we are able to successfully combine this approach with the technology now available to make human embryonic stem cells from reprogrammed skin cells. These cells can be transplanted into the muscle, and they cause muscle regeneration resulting in stronger contractility.”


Related Links:
University of Texas Southwestern Medical Center

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.